
FAX



Serial No.: 09/830,836
Filing Date: May 1, 2001
Applicant: Campbell et al.

Title: Pyrazolopyridine Derivatives as Selective COX-2 Inhibitors

Attached:
Certificate of transmission via facsimilie
Supplemental Response After Final

Thank you, Valerie Phillips

£

Certificate of Transmission by Facsimile (37 CFR 1.8)

I hereby certify that this Response to Office Action is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. 703-872-9306) on July 2,2003.

Valerie L. Phillips

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

gsk GlaxoSmithKline

Glaxo Wellcome Inc. PO Box 13398 Five Moore Drive Research Triangle Perk North Carolina 27709

Tel: 919 483 2100 www.gsk.com

9. 2003 8:04AM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application:

I. Campbell et al.,

Serial No.:

09/830,836

Examiner:

B. Robinson

Filing Date:

1 May 2001

Art Unit:

1625

PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS

Assistant Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL RESPONSE AFTER FINAL

Sir:

Further to the Office Action mailed 27 December 2002, the response filed 25 February 2003, the Interview with Examiner Alan Rotman on 8 July 2003 and the Advisory Action faxed to Applicants on 8 July 2003, please reconsider the instant application in view of the following remarks.

Remarks

Currently Claims 1-10, 14, 17-23 and 25-35 are pending.

The Final Rejection indicates that claims 1-10, 14, 17-18, 29 and 35 are allowed, claims 26-28 are rejected and claims 19-23 and 30-34 are withdrawn as directed toward non-elected species. The Final rejection fails to specify the status of pending claim 25, there is no rejection on the record for this claim and it was not withdrawn.

The Advisory Action indicates that claims 1-9, 14, 18, 29 and 35 are allowed, claims 26-28 are rejected and claims 19-23 and 30-34 are withdrawn and the Action fails to specify the status of claims 10, 17 and 25.